Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care

Panelists debate the treatment of relapsed/recurrent acute myeloid leukemia, comparing the potential of menin inhibitors to standard-of-care therapies, including chemotherapy and BCL2 inhibitors, in improving patient outcomes.

EP: 1.All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

EP: 2.AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

EP: 3.Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing

Now Viewing

EP: 4.Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care

Recent Videos